U.S. markets open in 5 hours 31 minutes
  • S&P Futures

    3,437.50
    +5.25 (+0.15%)
     
  • Dow Futures

    28,222.00
    +40.00 (+0.14%)
     
  • Nasdaq Futures

    11,658.75
    -2.00 (-0.02%)
     
  • Russell 2000 Futures

    1,617.60
    +2.80 (+0.17%)
     
  • Crude Oil

    41.14
    -0.56 (-1.34%)
     
  • Gold

    1,922.10
    +6.70 (+0.35%)
     
  • Silver

    25.09
    +0.11 (+0.44%)
     
  • EUR/USD

    1.1871
    +0.0042 (+0.36%)
     
  • 10-Yr Bond

    0.7970
    0.0000 (0.00%)
     
  • Vix

    29.45
    +0.27 (+0.93%)
     
  • GBP/USD

    1.3048
    +0.0101 (+0.78%)
     
  • USD/JPY

    105.0120
    -0.4580 (-0.43%)
     
  • BTC-USD

    12,191.17
    +1,134.17 (+10.26%)
     
  • CMC Crypto 200

    245.02
    +6.10 (+2.55%)
     
  • FTSE 100

    5,850.27
    -38.95 (-0.66%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

Global Sickle Cell Disease Clinical Trial Pipeline Highlights 2020 - ResearchAndMarkets.com

·2 mins read

The "Global Sickle Cell Disease Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

This report provides the most up-to-date information on key pipeline products in the global Sickle Cell Disease market. It covers emerging therapies for Sickle Cell Disease in active clinical development stages including early and late-stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Sickle Cell Disease pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Sickle Cell Disease pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Sickle Cell Disease pipeline products by company.

Short-term Launch Highlights:

Find out which Sickle Cell Disease pipeline products will be launched in the US and beyond to 2025.

Key Topics Covered:

1. Sickle Cell Disease Pipeline by Stages

2. Sickle Cell Disease Phase 3 Clinical Trial Insights

3. Sickle Cell Disease Phase 2 Clinical Trial Insights

4. Sickle Cell Disease Phase 1 Clinical Trial Insights

5. Sickle Cell Disease Preclinical Research Insights

6. Sickle Cell Disease Discovery Stage Insights

7. Appendix

8. Research Methodology

List of Tables

Table 1: Sickle Cell Disease Phase 3 Clinical Trials, 2020

Table 2: Sickle Cell Disease Phase 2 Clinical Trials, 2020

Table 3: Sickle Cell Disease Phase 1 Clinical Trials, 2020

Table 4: Sickle Cell Disease Preclinical Research, 2020

Table 5: Sickle Cell Disease Discovery Stage, 2020

List of Figures

Figure 1: Sickle Cell Disease Pipeline Molecules by Clinical Trials Stage, 2020

Figure 2: Sickle Cell Disease Phase 3 Clinical Trial Highlights, 2020

Figure 3: Sickle Cell Disease Phase 2 Clinical Trial Highlights, 2020

Figure 4: Sickle Cell Disease Phase 1 Clinical Trial Highlights, 2020

Figure 5: Sickle Cell Disease Preclinical Research Highlights, 2020

Figure 6: Sickle Cell Disease Discovery Stage Highlights, 2020

For more information about this report visit https://www.researchandmarkets.com/r/q8oym9

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200529005246/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900